AI-guided post-discharge care for premature coronary artery disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will compare an AI-enabled stratified management platform (SMART-CHD) to usual post-discharge care to see if the digital approach reduces a combined endpoint of all-cause death, myocardial infarction, stroke, and rehospitalization within 12 months and improves control of modifiable risk factors. Participants assigned to SMART-CHD install the mobile app after a brief supervised orientation and complete regular in-app surveys on lifestyle, labs, imaging, and clinical events, with OCR-enabled language models to capture results. The control group receives standard verbal and printed discharge instructions on medications, follow-up, and lifestyle advice. Outcomes are measured over a 12-month follow-up period to compare event rates and risk-factor trajectories between groups.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Patients with coronary heart disease aged 18-45 years;
2. The patient or a close family member is capable of using a smartphone and mobile application (App);
3. Willing to participate in the study and able to provide written informed consent.

Exclusion Criteria

1. Severe cognitive impairment;
2. Advanced-stage malignancy;
3. Life expectancy less than 12 months;
4. Severe multi-organ failure;
5. Refusal to provide written informed consent.

Where it's running

• Fuwai Hospital, Chinese Academy of Medical Sciences/National Center for Cardiovascular Diseases
  Beijing, Beijing Municipality, China Recruiting
• The First Affiliated Hospital of University of Science and Technology of China
  Hefei, Anhui, China Not yet recruiting
• Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen
  Shenzhen, Guangdong, China Not yet recruiting
• The First Hospital of Hebei Medical University
  Shijiazhuang, Hebei, China Not yet recruiting
• The Second Hospital Of Hebe Medical University
  Shijiazhuang, Hebei, China Not yet recruiting
• The First Affiliated Hospital of Henan University of Science and Technology
  Luoyang, Henan, China Not yet recruiting

Study contacts

• Study coordinator: Gao Prof. Gao, MD, PhD
• Email: sophie_gao@sina.com
• Phone: 010-88322413

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting future heart problems in young adults with premature coronary artery disease (MAP-CHD)

  This project will follow Chinese adults under 45 with premature coronary artery disease to see if clinical features and blood tests can predict future adverse heart events.

  Recruiting China National Center for Cardiovascular Diseases · Beijing · NCT07004452

• Evaluating VERVE-102 for lowering cholesterol in specific heart disease patients

  This study is testing a new gene-editing treatment called VERVE-102 to see if it can lower cholesterol levels in people with certain heart conditions.

  Recruiting at 27 sites Phase 1 Verve Therapeutics, Inc. · Dothan, Alabama and 26 other locations · NCT06164730

• NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa

  This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.

  Recruiting University of Eastern Finland · Savonlinna · NCT07820800

• Prospective cardiac surgery cohort to improve perioperative care

  A multi-center study will test a large, forward-looking database of adults undergoing heart surgery to better understand what affects short- and long-term outcomes.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07662317

• Mazdutide and coronary plaque in people with coronary artery disease and overweight or obesity

  This study tests whether mazdutide can slow or reduce coronary plaque build-up in adults with coronary artery disease who are overweight or obese.

  Recruiting Phase 4 China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07657676

• Understanding risk factors for cognitive problems in people with coronary heart disease

  In people with coronary heart disease, this study tests how metabolic factors and imaging features relate to cognitive impairment.

  Recruiting Beijing Anzhen Hospital · Beijing, China · NCT07657624

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.